NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+5 more ↓
67%
Finnrick rating
#246 of 344 ranked vendors
70 of 98 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Mai Peptide's purity-focus record is strongest where Retatrutide's later run cleaned up and Ipamorelin/Tesamorelin hold tight purity and fill, while GHK-Cu pairs high purity with fill and batch-ID gaps. Tirzepatide is volatile after purity misses and a failed-identity/0 mg test, and Cagrilintide has recent sub-cutoff purity on thin evidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Mai Peptide

Corporate and B2B records tie the retail brand to a Xi’an operator, while archives show a predecessor identity and parked domain. Shared shop910 infrastructure, CDN assets, payment scripts, and cloned testimonials map a wider storefront cluster.

21 pages7 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.77
83%
37
2
GHK-Cu
$0.06
80%
12
3
Ipamorelin
$0.90
75%
7
4
Tirzepatide
$0.33
63%
26
5
Cagrilintide
$2.40
58%
5
6
Tesamorelin
$1.80
52%
5
7
BPC-157
$0.70
44%
6
8
CJC-1295
$1.50
-
0
9
Glutathione
$0.00
-
0
10
NAD+
$0.02
-
0
11
PT-141
-
-
0
13
TB-500
$1.20
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%22 Feb 2026: 67%22 Feb 2026: 67%26 Feb 2026: 65%1 Mar 2026: 64%4 Mar 2026: 64%6 Mar 2026: 64%6 Mar 2026: 64%6 Mar 2026: 64%6 Mar 2026: 65%6 Mar 2026: 65%12 Mar 2026: 66%12 Mar 2026: 66%13 Mar 2026: 66%13 Mar 2026: 67%28 Apr 2026: 67%28 Apr 2026: 67%13 May 2026: 67%13 May 2026: 67%5 Jun 2026: 67%8 Jun 2026: 68%26 Jun 2026: 68%1 Jul 2026: 68%1 Jul 2026: 68%1 Jul 2026: 68%1 Jul 2026: 68%10 Jul 2026: 69%13 Jul 2026: 69%13 Jul 2026: 69%13 Jul 2026: 70%30 Jul 2026: 69%30 Jul 2026: 69%30 Jul 2026: 68%21 Aug 2026: 68%25 Aug 2026: 67%25 Aug 2026: 67%26 Aug 2026: 68%26 Aug 2026: 67%27 Aug 2026: 67%4 Sept 2026: 67%7 Sept 2026: 67%17 Sept 2026: current 67%67%67%67%Feb 26Sep 26
Free peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
Mai Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
7 Sep 2026
Pass
Tirzepatide
lab nameView COA
4 Sep 2026
Pass
Tirzepatide
lab nameView COA
27 Aug 2026
Fail
BPC-157
lab nameView COA
26 Aug 2026
Fail
Retatrutide
lab nameView COA
26 Aug 2026
Pass
Retatrutide
lab nameView COA
25 Aug 2026
Pass
Retatrutide
lab nameView COA
25 Aug 2026
Fail
GHK-Cu
lab nameView COA
21 Aug 2026
Fail
Tirzepatide
lab nameView COA
30 Jul 2026
Fail
GHK-Cu
lab nameView COA
30 Jul 2026
Fail
Tirzepatide
lab nameView COA
1-10 of 98

About Mai Peptide test results from Finnrick

Mai Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 98 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Mai Peptide peptides in this dataset are BPC-157 (6 tests), Cagrilintide (5 tests) and GHK-Cu (12 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 98 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply